Stock Taper
SCREENER COMPARE ANY 2 STOCKS
EDIT
EDITAS MEDICINE, INC.
NASDAQ
$3.16
▼ DOWN 4.24% (-0.14)

KEY STATISTICS

Market Cap$484.94 M
52w High$4.54
52w Low$1.66
Dividend Yield—
Frequency—
P/E-4.21
Volume3.27M
Shares Out.153.46M

COMPANY

LEADERSHIP

Gilmore O'Neill
CHIEF EXECUTIVE
Gilmore O'Neill

COMPENSATION 2026

Salary$686,574
Stock Awards$0
Incentive Plan Pay$375,164
All Other Comp.$8,980
Total$2,353,655

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 3, 2016
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
87

PRICE TARGET

Target High$6.00
Target Low$4.00
Target Median$5.00
Target Consensus$5.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$4.49M
NOV
9
MON

PRICE

$3.16 ▼ DOWN 4.24% (−$0.14)
$3.15$3.23$3.30$3.389:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.16

About Editas Medicine, Inc.

https://www.editasmedicine.com ↗

Editas Medicine is a Cambridge-based clinical-stage genome editing company developing CRISPR-based therapies for serious diseases, including blindness, blood disorders, and cancers, through proprietary gene editing platforms and strategic collabor...

INDUSTRY

Biotechnology

A PRODUCT EDITAS MEDICINE, INC. IS KNOWN FOR

EDIT-401
EDIT-401

EDIT-401 is an in vivo gene-editing therapy targeting high cholesterol, demonstrating potential to reduce LDL levels by ~90% by editing the LDLR gene, and is now Editas’s lead candidate focusing on cardiovascular diseases.

COMPETITORS

COMPETITOR
BEAM COMPARE
CRBU COMPARE
CRSP COMPARE
NTLA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Reportable Segment$7.54M $24.74M ▲$2.83M ▼$11.89M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
82
LISTED HERE
14
RANKED BY POSITION SIZE
VTS.AX
0.00% · 4.9M
XSU.TO
0.01% · 2.6M
SCHA
0.01% · 472.0K
R2SC.L
0.01% · 227.2K
PRFZ
0.01% · 118.7K
XRSU.L
0.01% · 91.5K
WBIO.L
0.81% · 86.3K
AVUS
0.00% · 76.2K
GNOM
0.24% · 69.8K
MEDX
0.46% · 25.0K
BIB
0.02% · 5.5K
TMFX
0.02% · 2.2K
FSEG
0.07% · 1.5K
RESM
0.02% · 279

INSTITUTIONAL OWNERSHIP

SHARES OWNED
56.23%
HOLDERS
327
TOP 12 OF 327 · RANKED BY POSITION SIZE
Tcg Crossover Management, LLC
11.1M sh · $36M
Blackrock, Inc.
10.6M sh · $34.31M
Adar1 Capital Management, LLC
8.9M sh · $28.8M
Ra Capital Management, L.P.
8.9M sh · $28.8M
Commodore Capital LP
8.9M sh · $28.8M
Vanguard Group Inc
8.2M sh · $16.83M
Blackrock Inc.
7.8M sh · $36.34M
Paradigm Biocapital Advisors LP
5.6M sh · $18.1M
Flagship Ventures Fund Iv General Partner LLC
5.0M sh · $120.91M
Renaissance Technologies LLC
4.0M sh · $9.81M
Opaleye Management Inc.
3.9M sh · $12.51M
Woodline Partners LP
3.6M sh · $11.52M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Daniel Goldman
Daniel Goldman
Sale
2023-04-10
 Donald Sternoff Beyer
Donald Sternoff Beyer
Sale (Full)
2021-04-14
 Donna Shalala
Donna Shalala
Sale (Full)
2019-06-04
SENATE TRADES
James Inhofe
James Inhofe
Sale (Full)
2019-02-04

INSIDER TRADES

★
DIRECTOR
Ellinor Patrick Thomas II
Purchase · 103.4K shares
2026-08-06
★
DIRECTOR:
Ellinor Patrick Thomas II
— · —
2026-08-06
★
OFFICER: SVP, CHIEF FINANCIAL OFFICER
Parison Amy
Sale · 678 shares
2026-08-03
★
OFFICER: EVP, CHIEF SCIENTIFIC OFFICER
Burkly Linda
Sale · 4.9K shares
2026-07-28

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
EQUAL WEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
Chardan Capital BUY Jones Trading BUY HC Wainwright & Co. BUY Wells Fargo EQUAL WEIGHT

SECTORS PEERS

PEERPRICE
ALLO$2.02COMPARE
CAPR$9.59COMPARE
KYTX$8.37COMPARE
CABA$3.12COMPARE
AVIR$5.36COMPARE
LYEL$14.53COMPARE
VNDA$5.29COMPARE
PRQR$2.29COMPARE